Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4014 | Thymosin+standard treatment Wiki | 1.00 |
| drug4755 | standard treatment Wiki | 1.00 |
| drug2755 | PD-1 blocking antibody+standard treatment Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death. The purpose of this study is to: - Determine the prevalence of SARS-CoV-2 carrier status over time in children and parents - Determine the prevalence of antibody development over time in children and parents - Compare carrier status and antibody development for children with asthma and/or other atopic conditions (e.g. eczema) versus children without asthma and/or other atopic conditions - Investigate the presence of SARS-CoV-2 exposure in historical samples from enrolled participants
Description: Included: Participants currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts. Calculated at the end of surveillance/study follow-up or fate, defined as follows: Time from entry until the first of the following events: Tests positive for SARS-CoV-2 RNA in nasal samples Is lost to follow-up or withdraws from the study End of study (Week 24) Fate at the end of follow-up: 1 (positive): If the participant tests positive for SARS-CoV-2 0 (censored): If the participant has no evidence of having had disease by the end of follow-up
Measure: Cumulative Incidence of SARS-CoV-2 RNA Detection in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period Time: Up to Week 24Description: Included: Participants currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts. Outcome definition: Detectable SARS-CoV-2-specific antibodies in serum biological specimen(s).
Measure: Percent of Index Participants and Their Household Contacts with Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period Time: Up to Week 24Description: Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria. Testing method: Positive test result(s) for SARS-CoV-2 RNA in nasal samples.
Measure: Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period Time: Up to Week 24Description: Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria. Outcome definition: Detectable SARS-CoV-2-specific antibodies in serum biological specimen(s).
Measure: Percent of Index Participants with Asthma and Other Atopic Disease with Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period Time: Through study completion, an average of 24 WeeksDescription: Nasal samples of participants currently or previously enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts that test positive for SARS-CoV-2, will undergo transcriptome analysis. Total RNA will be isolated for cDNA synthesis and amplification. Differential gene expression analysis be pursued.
Measure: Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period Time: Up to Week 24Description: Nasal samples of index participants that test positive for SARS-CoV-2 will be evaluated by transcriptome analysis. Differential gene expression analysis at different timepoints in the disease process will be analyzed. Definition of index participant(s): Prior and/or current NIH-funded clinical research study participant(s) who fulfill inclusion criteria.
Measure: Changes in the Nasal Transcriptome Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants with Asthma and Other Atopic Disease Compared to Index Participants without Atopic Disease Over the Study/Surveillance Period Time: Up to Week 24Description: An analysis of symptoms associated with positive SARS-CoV-2 RNA tests in nasal samples will be conducted. Included in analysis: Index participants and their household contacts.
Measure: Symptoms Associated with Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period Time: Up to Week 24Description: Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria. Tests:Positive for SARS-CoV-2 RNA in nasal samples
Measure: Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants using Topical Steroids Compared to Index Participants that are Not Using Topical Steroids Over the Study/Surveillance Period Time: Up to Week 24Description: Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria. Tests: Positive for SARS-CoV-2 RNA in nasal samples.
Measure: Cumulative Incidence of SARS-CoV-2 Detection in Nasal Samples Among Index Participants Using Topical, Oral, or Inhaled Steroids Compared to Index Participants that are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period Time: Up to Week 24Description: An exploratory analysis will be conducted for detection of possible associations, focusing on baseline demographic and environment factors and/or history of bronchiolitis prior history with the cumulative incidence of SARS-CoV-2 detection in nasal samples Test: Positive for SARS-CoV-2 RNA in nasal samples.
Measure: Analysis of Factors, Baseline and Prior History, for Possible Association with the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period Time: Baseline, Week 24Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports